STERIS announced strong Q4 2022 results with a 39% increase in revenue to $1.2 billion and adjusted EPS of $2.04. The company anticipates another record year of performance in fiscal year 2023, despite ongoing supply chain and inflation challenges.
Revenue increased by 39% as reported, with an 11% constant currency organic increase.
Reported EPS was $0.52, while adjusted EPS reached $2.04.
Healthcare revenue grew by 32% to $738.8 million.
Applied Sterilization Technologies (AST) revenue increased by 19% to $222.9 million.
For fiscal year 2023, STERIS anticipates constant currency organic revenue growth of approximately 11% and as reported revenue to increase approximately 12%. Adjusted earnings per diluted share are expected to be in the range of $8.55 to $8.75. Capital expenditures are anticipated to be approximately $330 million and free cash flow is expected to be approximately $675 million.
Visualization of income flow from segment revenue to net income